HotSheets 2007
- President’s Message: Taking Action in 2007
- Feb Conf Call: "Intimacy & Prostate Cancer"
- Companies, Chapters Signing Up for Sneakers@Work Day
- New Tests of Dendreon’s Prostate Cancer
- Doc Moyad’s What Works and What is Worthless Column: Vitamin D—Part II
- Read more..
- President’s Message: “What Is Awareness?
- Special Thanks to Joe Piper
- The Year in Prostate Cancer: Part I of II
- Doc Moyad’s What Works and What is Worthless Column: Vitamin D—Part III
-
Feb. 13th Conference Call:
Intimacy & Prostate Cancer -
2nd Annual Us TOO Online Auction
Announced, Seeking Donated Items for Bid - Read more..
- Survivor Rate Highest with Prostatectomy for Localized Prostate Cancer
- New Members for Us TOO Board of Directors
- The Year in Prostate Cancer, Part II
- Medicare Part D and Erectile Dysfunction
- Leading by Example
- PROVENGE® Granted FDA Priority Review
- Read more..
- Special Burning Issues Supplement: Highlights from the 2007 Multidisciplinary Prostate Cancer Symposium – February 21-24, 2007, Orlando, FL
- GPC Biotech Provides Satraplatin for Free
- Calcitriol with Docetaxel Boosts Survival
- The Year in Prostate Cancer – Part 3
- Estrogen Therapy: DES (Diethylstilbestrol)
- Doc Moyad’s What Works and What is Worthless Column: Zinc supplementation?
- Read more..
- Special Burning Issues Supplement: Prostate cancer and incontinence: coping strategies and treatment options
- MRI in Managing Prostate Cancer
- FDA Panel Backs New Prostate Vaccine
- Adjuvant ADT Can “Cure” Nonmetastasized Prostate Cancer
- Alendronate Increases BMD in Prostate Cancer Patients Receiving ADT
- Doc Moyad’s What Works and What is Worthless Column—Lycopene
- Read more..
- Doc Moyad’s What Works and What is Worthless Column—Provenge®
- Cell Genesis Reports Phase II Results with GVAX Immunotherapy
- A Survivor Reviews the 2007 ASCO Prostate Cancer Symposium
- UCSD Researchers Report Ability to Detect Cancer at Earliest, Curable Stage
- New Blood Test for Prostate Cancer—Can EPCA-2 be on the Horizon?
- Possible New Cancer Treatment? Antifungal Drug Stops Blood Vessel Growth
- Read more..
- New AUA Prostate Cancer Guidelines
- FDA Requirements for Provenge® Licensure
- Consider Source of Localized Prostate Cancer Recommendations
- Dendreon Sued after Provenge’s Ok Put Off
- 223Radium in Hormone-Refractory Cancer
- Update:Outcomes with Primary Therapy for Intermediate Risk Prostate Cancer
- Read more..
- New Data from ASCO on SPARC Trial
- Us TOO University in Austin, Texas “A Marvelous Evening”
- Survivorship Care Plan Is an Important Part of Cancer Care
- Sneakers@ Work Day, Great Fun, Great Success
- F-18 Fluor Choline PET/CT Assesses Bone Metastases in Prostate Cancer
- New Procedure Minimizes Post-Prostatectomy Incontinence
- Read more..
- Court Sees No Right to Unapproved Drugs
- FDA Requests More Data on Satraplatin
- Hormone Inhibitor Promising For Hard-to-Treat Prostate Cancer
- FDA Sued Over Provenge Delay
- Botox for Treating Prostate Problems
- Doc Moyad’s “No Bogus Science” Column
- Friday the 13th Lucky for Prostate Pointers
- Read more..
- CMS Proposal Would Virtually Eliminate Medicare Clinical Trials Coverage
- Statins Fail to Cut the Androgens that Fuel Prostate Cancer
- Stress Management before Prostatectomy
- First Biomarker Discovered that Predicts Prostate Cancer Outcome
- Prostate Px® Test Results Published
- Doc Moyad’s What Works and What is Worthless Column
- Read more..
- Charity Navigator Gives Us TOO 4-Star Rating
- Gleason Score and Prostate Cancer Prognosis
- New Study Refutes Belief that Black Men Have More Aggressive Prostate Cancer
- Us TOO Reaches Out to Federal Employees and Military
- Nomogram Can Predict Life Expectancy
- oc Moyad’s What Works and What is Worthless Column—Ginseng
- Read more..
- Us TOO’s 2006 Annual Report Now Available
- New Free Kits for Newly-Diagnosed Men
- Survival Analysis from the SPARC Trial
- Us TOO University Chicago Program a Success
- October 30th Intimacy Teleconference a Success
- Biopsy Site Affects Prostate Cancer Detection
- Read more..